Treatment of insulin resistance in a patient with obesity and chronic heart failure
AbstractThe aim of the article is to demonstrate the possibility of using the drug Subetta® in the treatment of insulin resistance in a patient with arterial hypertension, coronary heart disease, chronic heart failure and obesity on a clinical example.
Material and methods. A clinical case of a patient with insulin resistance and chronic heart failure with preserved ejection fraction is presented.
Results. The addition of the drug Subetta® to therapy in a patient with insulin resistance and chronic heart failure gave a significant clinical effect. The body weight and the volume of visceral adipose tissue decreased, which improved the sensitivity of peripheral tissues to insulin and, as a result, the indicators of carbohydrate and lipid metabolism, the level of hepatic transaminases.
Conclusion. The solution to the problem of insulin resistance is possible by prescribing combination therapy that affects the insulin receptor. The complex effect, including compliance with dietary recommendations, the use of pathogenetically justified therapy with Subetta®, both in combination therapy and in monotherapy, led to a decrease in body weight and waist circumference, which ultimately led to a decrease in insulin resistance, as evidenced by an improvement in carbohydrate and lipid metabolism.
Keywords:insulin resistance; obesity; carbohydrate metabolism disorders; dyslipidemia; metabolic syndrome; Subetta®
Funding. The study had no sponsor support.
Conflict of interest. The authors declare no conflict of interest.
For citation: Ostroumova O.D., Klepikova M.V., Plotnikova N.A., Gusenbekova D.G. Treatment of insulin resistance in a patient with obesity and chronic heart failure. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2023; 12 (2): 95–100. DOI: https://doi.org/10.33029/2304-9529-2023-12-2-95-100 (in Russian)
References
1. Violan C., Foguet-Boreu Q., Flores-Mateo G., et al. Prevalence, determinants and patterns of multimorbidity in primary care: A systematic review of observational studies. PLoS One. 2014; 9 (7): 1–9. DOI: https://doi.org/10.1371/journal.pone.0102149
2. Hovstadius B., Astrand B., Petersson G. Dispensed drugs and multiple medications in the Swedish population: An individual-based register study. BMC Clin Pharmacol. 2009; 9: 11. DOI: https://doi.org/10.1186/1472-6904-9-11
3. Balanova Yu.A., Shalnova S.A., Deev A.D., Imaeva A.E., Kontsevaya A.V., Muromtseva G.A., et al. Obesity in russian population – prevalence and association with the non-communicable diseases risk factors. Rossiyskiy kardiologicheskiy zhurnal [Russian Journal of Cardiology]. 2018; (6): 123–30. DOI: https://doi.org/10.15829/1560-4071-2018-6-123-130 (in Russian)
4. Tsygankova O.V., Evdokimova N.E., Veretyuk V.V., Latyntseva L.D., Ametov A.S. Insulin resistance and heart failure with preserved ejection fraction. Pathogenetic and therapeutic crossroads. Sakharnyy diabet [Diabetes Mellitus]. 2022; 25 (6): 535–47. DOI: https://doi.org/10.14341/DM12916 (in Russian)
5. Lee S.H., Park S.Y., Choi C.S. Insulin resistance: from mechanisms to therapeutic strategies. Diabetes Metab J. 2022; 46 (1): 15–37. DOI: https://doi.org/10.4093/dmj.2021.0280
6. Martyushev-Poklad A.V., Yankevich D.S., Petrova M.V., Savitskaya N.G. Two models of insulin resistance development and the strategy to combat age-related diseases: literature review. Problemy endokrinologii [Problems of Endocrinology]. 2022; 68 (4): 59–68. DOI: https://doi.org/10.14341/probl13090 (in Russian)
7. . Vaisberg A.R., Tarlovskaya E.I., Fomin I.V., et al. Carbohydrate metabolism disorders in patients with heart failure: data from the local registry. Rossiyskiy kardiologicheskiy zhurnal [Russian Journal of Cardiology]. 2021; 26 (3): 4330. DOI: https://doi.org/10.15829/1560-4071-2021-4330 (in Russian)
8. Ritchie R.H., Abel E.D. Basic mechanisms of diabetic heart disease. Circ Res. 2020; 126 (11): 1501–25. DOI: https://doi.org/10.1161/CIRCRESAHA.120.315913
9. Saotome M., Ikoma T., Hasan P., et al. Cardiac insulin resistance in heart failure: the role of mitochondrial dynamics. Int J Mol Sci. 2019; 20 (14): 3552. DOI: https://doi.org/10.3390/ijms20143552
10. Goldberg I.J., Trent C.M., Schulze P.C. Lipid metabolism and toxicity in the heart. Cell Metab. 2012; 15 (6): 805–12. DOI: https://doi.org/10.1016/j.cmet.2012.04.006
11. Lu T., Forgetta V., Yu O.H.Y., et al. Polygenic risk for coronary heart disease acts through atherosclerosis in type 2 diabetes. Cardiovasc Diabetol. 2020; 19 (1): 12. DOI: https://doi.org/10.1186/s12933-020-0988-9
12. Diaz-Juarez J., Suarez J.A., Dillmann W.H., et al. Mitochondrial calcium handling and heart disease in diabetes mellitus. Biochim Biophys Acta Mol Basis Dis. 2021; 1867 (1): 165984. DOI: https://doi.org/10.1016/j.bbadis.2020.165984
13. Tentolouris A., Eleftheriadou I., Tzeravini E., et al. Endothelium as a therapeutic target in diabetes mellitus: From basic mechanisms to clinical practice. Curr Med Chem. 2020; 27 (7): 1089–131. DOI: https://doi.org/10.2174/0929867326666190119154152
14. Popyhova E.B., Stepanova T.V., Lagutina D.D., et al. The role of diabetes in the onset and development of endothelial dysfunction. Problemy endokrinologii [Problems of Endocrinology]. 2020; 66 (1): 47–55. DOI: https://doi.org/https://doi.org/10.14341/probl12212 (in Russian)
15. Braunwald E. Diabetes, heart failure, and renal dysfunction: The vicious circles. Prog Cardiovasc Dis. 2019; 62 (4): 298–302. DOI: https://doi.org/10.1016/j.pcad.2019.07.003
16. Di Angelantonio E., Gao P., Khan H., et al. Glycated hemoglobin measurement and prediction of cardiovascular disease. JAMA. 2014; 311 (12): 1225–33. DOI: https://doi.org/10.1001/jama.2014.1873
17. Solis-Herrera C., Triplitt C., Cersosimo E., et al. Pathogenesis of type 2 diabetes mellitus. 2021. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc. 2000.
18. Kosareva O.V., Dolgikh Yu.A., Sharonova L.A. Use of Subetta® in the treatment of impaired glucose tolerance in a patient with metformin intolerance (clinical case). Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2022; 11 (4): 95–100. DOI: https://doi.org/10.33029/2304-9529-2022-11-4-95-100 (in Russian)
19. Gorbunov E.А., Nicoll J., Kachaeva E.V., Tarasov S.А., Epstein О.I. Subetta increases phosphorylation of insulin receptor β-subunit alone and in the presence of insulin. Nutr Diabetes. 2015; 5 (7): e169. DOI: https://doi.org/10.1038/nutd.2015.20
20. Gorbunov E.A., Nicoll J., Myslivets A.A., et al. Subetta increases the sensitivity of human muscle cells to insulin. Byulleten’ eksperimental’noi biologii i meditsiny [Bulletin of Experimental Biology and Medicine]. 2015; 159 (4): 454–6. DOI: https://doi.org/10.1007/s10517-015-2992-8
21. Mokdad A.H., Bowman B.A., Ford E.S., et al. The continuing epidemics of obesity and diabetes in the United States. JAMA. 2001; 286 (10): 1195–200. DOI: https://doi.org/10.1001/jama.286.10.1195
22. Hauner H. Obesity and diabetes. In Textbook of Diabetes. Chichester: John Wiley & Sons, 2017. https://doi.org/10.1002/9781118924853.ch16.
23. Perseghin G., Ghosh S., Gerow K., et al. Metabolic defects in lean nondiabetic offspring of NIDDM parents: a cross-sectional study. Diabetes. 1997; 46: 1001–9.
24. Balukova E.V., Baryshnikova N.V., Belousova L.N. Nonalcoholic fatty liver disease: current state of problem. Farmateka. 2016; 2: 63–8. (in Russian)
25. Mkrtumyan A., Ametov A., Demidova T. et al. A new approach to overcome insulin resistance in patients with impaired glucose tolerance: the results of a multicenter, double-blind, placebo-controlled, randomized clinical trial of efficacy and safety of Subetta. J Clin Med. 2022; 11 (5): 1390. DOI: https://doi.org/10.3390/jcm11051390